Barth Syndrome Treatment Market is driven by rising prevalence of Barth syndrome
Barth syndrome is a rare genetic disorder characterized by muscle weakness,delayed growth, fatigue with exercise and enlarged heart or cardiomyopathy. Barth syndrome affects mostly males and symptoms often begin in infancy or early childhood. The exact prevalence is unknown but it is estimated that Barth syndrome affects1in 300,000 to 400,000 newborn males. Treatment focuses onmanaging symptoms and treating associated medical problems.
The Global Barth Syndrome Treatment Market is estimated to be valued at USD 160.02 billion in 2025 and is expected to exhibit a CAGR of 13.4% over the forecast period 2025-2032.
Key Takeaways
Key players operating in the Barth syndrome treatment market are Takeda Pharmaceutical Company Limited, Pfizer Inc., AbbVie Inc., and Eiger BioPharmaceuticals Inc.
Market drivers
The rising prevalence of Barth syndrome is the major factor driving the Barth Syndrome Treatment Market Growth. According to Barth Syndrome Foundation, it is estimated that Barth syndrome affects 1 in 300,000 to 400,000 newborn males. Furthermore, lack of awareness about the disease and difficulties in diagnosis also contributes to the increased prevalence. Hence, the growing disease prevalence is anticipated to propel the market growth during the forecast period.
Get More Insights on Barth Syndrome Treatment Market
Get this Report in Japanese Language- バルト症候群治療市場
Get this Report in Korean Language- 바르트 증후군 치료 시장
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian